论文部分内容阅读
目的 观察前列腺素E1(PGE1)对慢性重型肝炎患者血清可溶性白细胞介素 - 6受体 (SIL - 6R)及其 β链(sgp130 )的影响。方法 应用酶联免疫吸附法检测 16例慢性重型肝炎患者经PGE1治疗前后血清SIL - 6R、sgp130的动态变化。结果 慢性重型肝炎患者血清SIL - 6R、sgp130水平较健康对照组明显升高 (P <0 .0 1) ,PGE1治疗后血清SIL - 6R、sgp130水平较治疗前明显下降 (P <0 .0 1) ,且治疗组死亡率明显下降 (P <0 .0 1)。结论 监测血清SIL - 6R、sgp130水平能反映慢性重型肝炎的肝损伤程度及判定预后 ;PGE1能纠正慢性重型肝炎患者的免疫功能紊乱 ,减轻肝脏坏死和炎症细胞浸润
Objective To investigate the effects of prostaglandin E1 (PGE1) on serum soluble interleukin - 6 receptor (sIL - 6R) and sgp130 in patients with chronic severe. Methods Serum levels of SIL - 6R and sgp130 in 16 patients with chronic severe hepatitis were measured by enzyme - linked immunosorbent assay before and after PGE1 treatment. Results The levels of serum SIL - 6R and sgp130 in patients with chronic severe hepatitis were significantly higher than those in healthy controls (P <0.01). The levels of serum SIL - 6R and sgp130 in patients with chronic severe hepatitis were significantly lower than those before treatment (P <0.01) ), And the treatment group mortality decreased significantly (P <0.01). Conclusions Monitoring serum levels of SIL - 6R and sgp130 can reflect the degree of liver injury and prognosis in patients with chronic severe hepatitis. PGE1 can correct immune dysfunction in patients with chronic severe hepatitis and relieve liver necrosis and inflammatory cell infiltration